Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
August 1, 2024
Earnings Call Speaker Segments
Chris Taylor
executiveThanks, operator. Hello, everyone, and good morning. It's great to have you join Agios's conference call and webcast, where we'll go over our financial results for the second quarter of 2024 along with recent business highlights. Slides for today's call can be found in the Investors section on our website, agios.com. With me today are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Before we begin, I want to remind all of you that certain statements made today will include forward-looking statements. Due to various risks, uncertainties, and other factors, including those described in our most recent filings with the SEC as well as any other future filings we may make with the SEC, actual events and results could differ materially from those expressed or implied by any forward-looking statements. With that said, I'm happy to hand the call over to Brian.
Brian Goff
executiveThank you, Chris. Good morning to all of you, and we appreciate you being here. At Agios, our purpose is to create and bring to patients transformative therapies that lift up and lengthen the lives of those dealing with rare diseases. The basis for our work draws on mitapivat's innovative way of working, which enhances red blood cell health in general and has been a major factor behind the encouraging clinical results we have reported over the past several years. I am very pleased to share that we kept up our favorable trajectory during Q2, with a number of important milestones made public during this quarter. To begin, we reported that the Phase III ENERGIZE-T trial of mitapivat achieved its primary endpoint as well as every key secondary endpoint among adults suffering from transfusion-dependent alpha- or beta-thalassemia. It is worth noting that ENERGIZE-T stands as the initial Phase III trial to show efficacy for an oral disease-modifying therapy in transfusion-dependent alpha- and beta-thalassemia. Next, findings from the successful Phase III ENERGIZE trial of mitapivat in adults with alpha- or beta-thalassemia who do not receive regular transfusions were delivered by prominent KOLs across 2 presentations at the latest European Hematology Association Congress held in Madrid, one of which was a plenary session. When considered alongside the favorable results from ENERGIZE-T, we intend to file an sNDA for mitapivat in thalassemia drawing on all data available from both ENERGIZE and ENERGIZE-T before 2024 ends, pursuing a label encompassing individuals living with every subtype of thalassemia. Third, we shared that Agios has reached an agreement to divest its rights to a 15% royalty on potential U.S. net sales of Servier's vorasidenib via Royalty Pharma. Per the agreement's terms, Agios is set to obtain an upfront payment of $905 million once the FDA approves vorasidenib. Cecilia will go over the specifics shortly, and I want to express my gratitude to her for steering the process and putting together an outstanding agreement for Agios, our shareholders, and a win-win for both Agios and Royalty Pharma; this deal will give us the financial independence to get ready for possible launches in thalassemia and sickle cell disease as we build a multibillion-dollar PK activation franchise, along with the capacity to expand our pipeline when opportunities arise. And fourth, only this morning, we released top line data from the Phase III ACTIVATE-KidsT Study of mitapivat in children with PK deficiency who receive regular transfusions. This is genuinely a groundbreaking study for Agios, a first pediatric trial of mitapivat, and it reflects our dedication to exploring mitapivat's potential as a therapy for children with rare diseases. We are also happy to share that enrollment in the ACTIVATE-Kids Study is now complete, and we anticipate the top line readout in 2025. With this progress as a foundation, we are eager for a number of further milestones on the horizon, among them finishing enrollment in the Phase III portion of the RISE UP Study of mitapivat in sickle cell disease before this year concludes and reporting data in the following year. Sarah will give a thorough update on our advancements and forthcoming milestones throughout R&D in just a few minutes. Thanks to the steady, persuasive results we've seen throughout the mitapivat development program, along with the serious unmet need that exists in every disease area we're targeting, we think mitapivat could change the trajectory of several hemolytic anemias by making red blood cells healthier, and could grow into a multibillion-dollar franchise. Drawing on the encouraging findings from the ENERGIZE and ENERGIZE-T trials of mitapivat, which collectively cover every thalassemia subtype, our growing commercial team is getting ready for a possible U.S. launch of mitapivat in thalassemia during 2025, plus a possible sickle cell disease launch in 2026. In a little while, Tsveta will walk through the thalassemia market opportunity in more depth, along with how thoroughly the team has prepared for launch, and will also give an update on the PK deficiency launch now underway. In this morning's news release, we were pleased to share 2 announcements concerning PYRUKYND's commercialization beyond the U.S. First, a distribution agreement has been signed with NewBridge Pharmaceuticals, a prominent company in the Gulf region; and second, mitapivat has been granted Breakthrough Medicine Designation by the Saudi FDA. Lastly, as Cecilia will tell you, we closed the second quarter in a strong cash position, holding roughly $645 million in cash and investments on the balance sheet, and we could strengthen that cash position further by another $1.1 billion if vorasidenib wins potential FDA approval. I'll now hand the call to Sarah.
Sarah Gheuens
executiveBrian, thank you. We were excited to announce, earlier today, the topline findings from our Phase III ACTIVATE-KidsT trial, which evaluated mitapivat in pediatric PK deficiency patients undergoing routine transfusions. No prior Phase III trial had generated results for this group, and this marks Agios's first fully completed pediatric program for mitapivat. Additionally, we can confirm that patient accrual is now complete for the companion ACTIVATE-Kids trial, which examines mitapivat in children with PK deficiency who do not receive transfusions on a regular basis. Topline results from that second trial are expected to be shared next year, and we plan to examine the full set of data from both ACTIVATE-KidsT and ACTIVATE-Kids. Now, I'd like to discuss the ACTIVATE-KidsT findings that came out today. This initial slide illustrates that our program for Pediatric PK Deficiency is made up of two Phase III trials. These are evaluating pediatric patients who receive regular transfusions and those who do not, in ACTIVATE-KidsT and ACTIVATE-Kids, respectively. Approximately 20% of the overall PK deficiency patient population is children, and there are no approved treatments for pediatric PK deficiency. Now, regarding the top line results we announced this morning for the ACTIVATE-KidsT trial: 49 patients in total were enrolled, and they were randomized 2:1 to receive either mitapivat twice daily or a placebo. The study includes a 32-week double-blind period, which is then followed by an open-label extension period. In the mitapivat group, 30 out of 32 patients finished the double-blind phase, while 16 of 17 patients in the placebo group did the same. This morning's news release mentioned that, by applying Bayesian methodology, the prespecified statistical threshold for the primary endpoint in ACTIVATE-KidsT was not achieved when borrowing data from the adult ACTIVATE-T study at either low or moderate levels. Clinically, the findings mattered, since transfusion-free response and normal hemoglobin response—two important secondary endpoints here—appeared exclusively among those receiving mitapivat. On the call, transfusion reduction response was characterized as a drop of at least 33% in total red blood cell transfusion volume between weeks 9 and 32 of the double-blind period — adjusted for weight and the actual duration of study drug, and set against historical transfusion volume standardized by weight over 24 weeks. In the mitapivat group, 28.1% of patients hit that transfusion reduction response, versus 11.8% in the placebo group. Beyond that, more patients on mitapivat than on placebo reached the secondary endpoints of transfusion-free response and normal hemoglobin response, both assessed from week 9 through week 32 of the double-blind period. In the mitapivat group, six patients—close to 20%—experienced a transfusion-free response, meaning they needed no red blood cell transfusions, while nobody in the placebo group did. A normal hemoglobin response, defined as hemoglobin levels reaching normal limits on at least one occasion, 8 weeks or longer following a transfusion, was achieved by 4 patients on mitapivat versus 0 on placebo. Regarding safety, the profile observed for mitapivat was consistent with what has previously been reported in adults with PK deficiency who undergo chronic transfusions. Looking at the study's double-blind treatment period, the percentage of patients experiencing adverse events was comparable between those on mitapivat and those on placebo, and no one stopped study treatment because of AEs; a more detailed look at the Phase III ACTIVATE-KidsT data is something we intend to share at a medical meeting in the near future. It is our hope that this trial becomes the first among multiple pediatric studies to deliver a meaningful difference for children living with rare hemolytic anemia, such as thalassemia and sickle cell disease. Now shifting to what we have achieved in thalassemia: a summary of findings from the Phase III ENERGIZE study was delivered during a plenary session at the June EHA meeting by Dr. Ali Taher of the American University of Beirut Medical Center; additionally, a poster covering health-related quality of life and patient-reported outcome measures was presented by Dr. Kevin Kuo of the University of Toronto, along with an investor webcast. More specifics on efficacy and safety were shared. Significantly, patients who received mitapivat showed gains across multiple health-related quality of life measures, among them fatigue and walking capacity. Additionally, last month we were very happy to share favorable top-line results from the Phase III ENERGIZE-T trial of mitapivat in transfusion-dependent thalassemia. This makes mitapivat the first oral disease-modifying therapy demonstrating efficacy in transfusion-dependent alpha- and beta-thalassemia. Let me now briefly go over how that trial was designed and what it showed. The study has a 48-week double-blind phase, after which comes an open-label extension. A total of 258 patients were enrolled and assigned randomly in a 2:1 ratio to get either 100 mg mitapivat twice daily or placebo. The trial hit its main goals for how well it cut down on transfusions. We define that as dropping transfused red blood cell units by at least half, plus a decrease of 2 units or more, across any 12 consecutive weeks up to week 48, measured against where patients started. On that primary endpoint, 30.4% of patients got there, compared with 12.6% in the placebo group. The gap was highly statistically significant, with a p-value of 0.0003. Mitapivat also delivered statistically significant drops, versus placebo, on other transfusion reduction response measures, based on the 3 key secondary endpoints. Here's how that part of the call went: the first goal was cutting transfused red blood cell units by at least half across any 24-week stretch that ran consecutively, all the way out to week 48, measured against where patients started. The second was a drop of 33% or more in those same transfused units from week 13 through week 48 relative to baseline. And the third called for a reduction of 50% or greater in transfused red blood cell units over that same week 13 to week 48 window, again compared with baseline. On top of that, among patients on mitapivat, the secondary endpoint of transfusion independence was hit by 9.9% of them—which means no transfusions at all for at least 8 weeks in a row, continuing through week 48—while just 1.1% of the placebo arm did the same. And lastly, across the 48-week double-blind period, adverse event rates looked comparable between the mitapivat and placebo groups, with 5.8% of mitapivat patients having an AE that resulted in discontinuation, versus 1.2% of placebo patients; we're eager to present a deeper analysis of this data at a medical meeting soon. All told, results from ENERGIZE and ENERGIZE-T powerfully reinforce mitapivat's potential to serve as a foundational, convenient oral option for every subtype of thalassemia—alpha- and beta-thalassemia, plus transfusion-dependent and non-transfusion-dependent thalassemia. We remain on schedule to submit an sNDA including all data from both studies before this year ends, pursuing a label covering people living with every subtype of thalassemia. Brian mentioned it, and we're glad to share that mitapivat has received a Breakthrough Medicine Designation from the SFDA, which is the Saudi FDA. The purpose of this breakthrough medicine program is to accelerate and simplify how new drugs are developed and reviewed when they address unmet medical need in treating serious or life-threatening conditions. Mitapivat is one of the earliest products to receive the Breakthrough Medicine Designation, and together with our new partner, NewBridge, we look forward to working with regulators. Turning to sickle cell disease, enrollment continues to progress in the Phase III portion of RISE UP for mitapivat, and we're still on track to complete enrollment before the end of this year. Given the encouraging results seen in the Phase II segment of RISE UP, as well as favorable findings from studies involving other hemolytic anemias, we believe mitapivat could emerge as a convenient first-in-class and best-in-class therapy that enhances red blood cell health for individuals with sickle cell disease. We look forward to sharing top line data from the Phase III segment of RISE UP in the coming year, and to mitapivat's capacity to tackle the significant unmet need in this condition by alleviating anemia, lowering sickle cell pain crises, and enabling patients to feel improved with reduced fatigue. To wrap up, every goal tied to the remainder of our progressing pipeline is still on track for delivery on time. That covers opening enrollment for the Phase IIb trial testing larger doses of AG-946, our innovative PK activator that now carries the name tebapivat, in lower-risk MDS. We look forward to providing more specifics once the study gets underway shortly. I'll pass things along to Tsveta at this point.
Tsveta Milanova
executiveThank you, Sarah. Right now, receiving a thalassemia diagnosis can feel overwhelming for those affected and those close to them. We had just come back from the Cooley's Anemia Foundation Patient and Family Conference held in Atlanta, where we listened to numerous moving accounts that underscored how severely thalassemia can disrupt the lives of patients and their families. Every subtype of thalassemia carries elevated rates of significant morbidities, diminished quality of life, and an increased chance of dying early. Patients find it hard to manage this condition, since available treatments are few, and both the disease burden and the related expense of care are considerable. Drawing on the encouraging results from our ENERGIZE and ENERGIZE-T trials, our goal is to revolutionize how this disease is treated and to deliver the first approved therapy indicated for every thalassemia subtype. Roughly 6,000 adults in the U.S. carry a thalassemia diagnosis. About 4,000 of them are not transfusion dependent; within the U.S., no oral treatments have been approved for people living with thalassemia. And when it comes to non-transfusion-dependent disease, nothing at all is approved. Our commercial team is busy getting ready to meet this substantial unmet need, with a possible U.S. launch of PYRUKYND for thalassemia happening next year. Beyond the steady and convincing results from the mitapivat development program, we see 3 main elements that could help drive uptake of PYRUKYND for thalassemia in the U.S. First, because newborn screening is available and ICD-10 codes are well established, thalassemia gets diagnosed at a high rate, and many patients receive their diagnosis before reaching adulthood. Second, patients and providers alike cluster around a small group of centers, and roughly 50% of all diagnosed patients receive care at fewer than 150 affiliated practices, which gives us a clear target for the initial launch. And third, because certain Centers of Excellence took part in our clinical trials, a number of treating physicians already possess direct experience with mitapivat. Considering all of this, we believe our position is strong when it comes to offering a potential foundational treatment choice for thalassemia patients, no matter the subtype. As we keep moving toward a possible U.S. launch, our team has its attention on 4 essential launch preparation areas. First, we are continuing to carry out thorough market research and claims data analysis so we can sharpen our market insights and physician targeting further. Second, in May we kicked off a fresh disease education campaign aimed at both patients and clinicians, one that shines a light on the long-term complications and the burden of disease across every thalassemia subtype. I'll say a bit more about that campaign shortly. Third, we are carrying out a careful expansion of our commercial and medical teams to get the organization to the right size for a successful launch in this bigger, though still rare, market. And fourth, our market access team has already begun payer discussions centered on disease state education. I take pride in the wide access our team has secured for PYRUKYND in PK deficiency, and we anticipate achieving the same strong result in thalassemia. Turning to Slide 24, you'll see a sample of the messaging our team has been deploying in fresh disease state education efforts aimed at patients as well as healthcare providers. The goals here are to shine a light on the burden thalassemia places on people and to promote monitoring and management of the disease, and with that in mind our team keeps hammering home the points shown, with particular emphasis on overturning the belief that patients who are not transfusion dependent face a smaller degree of risk. Up next is a visual from our campaign. It shows the way we get across to physicians that significant morbidity risk may be present no matter what a thalassemia patient's history of transfusions looks like. Feedback so far has been highly favorable, as these visuals and messages are landing well with patients and providers alike. I noted earlier that our team keeps sharpening its grasp of the market; this slide presents findings from a market research study conducted recently that shed light on which clinical characteristics healthcare providers rank as most important when deciding to prescribe PYRUKYND: hemoglobin levels, transfusion burden, fatigue, and iron overload. Beyond the U.S., roughly 70,000 thalassemia patients live in the Gulf Cooperation Council, or GCC, region. Additionally, several of the area's top treatment centers took part in our clinical trials. We are happy to report today that we have signed a distribution agreement with NewBridge Pharmaceuticals to get ready for a possible commercialization of PYRUKYND across the GCC region. NewBridge, a top specialty company based in Dubai, will handle commercialization of PYRUKYND in Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates; we're thrilled to team up with NewBridge as we work toward a potential commercialization in that part of the world. As Slide 27 indicates, within the GCC it is Saudi Arabia that holds the biggest patient population. We take considerable pride in how the team worked to successfully obtain a Breakthrough Medicine Designation for mitapivat thalassemia, which the SFDA, Saudi FDA, awarded. Per the final bullet, the route to access in each GCC country typically starts with a price established at the regulatory level, after which comes access involving health authorities, local institutions, the private sector, and national standards. Those elements are central to the process, and we anticipate working through them over time alongside our partner, NewBridge. Let me shift now to an update on the ongoing launch of PYRUKYND in PK deficiency. During the second quarter of 2024, net PYRUKYND revenue came to $8.6 million, up from $8.2 million in the first quarter of 2024. Within the U.S., 201 patients in total have completed a prescription enrollment form, among them 13 during the second quarter of 2024, which marks a 7% rise over the prior quarter. That has resulted in 128 net patients on therapy, a 7% rise over the prior quarter. The patients on therapy keep coming from an expanding and varied prescriber base made up of 173 physicians, and they reflect a wide range of demographics and disease manifestations that aligns with the adult PK deficiency population in the U.S. We're still heartened by how long patients stay on therapy, and we're staying disciplined about pinpointing the providers most likely to have people with PK deficiency under their care. Our sense is that these capabilities will keep getting stronger as the PKD launch proceeds—things like precise targeting analytics, education and awareness for both patients and physicians, and patient access—and that this will give us a solid base for getting the most out of possible upcoming U.S. launches of mitapivat, such as thalassemia in 2025 and sickle cell disease in 2026. Most of all, the chance to deliver a new treatment option to these underserved patient groups excites and motivates us; with that, I'll hand the call to Cecilia.
Cecilia Jones
executiveThank you, Tsveta. You can find our financial results for the second quarter of 2024 in the press release that went out this morning, and additional information will appear in our 10-Q, which we'll be filing later on today. Now I'd like to take a moment to give you some background and walk through several important items. Net revenue for PYRUKYND in the second quarter of 2024 came to $8.6 million, which is $1.9 million higher than what we recorded in the second quarter of 2023. As is typical with other rare disease launches, gross to net has been running, and should continue to run, between 10% and 20% on an annual basis. As we shift the organization's attention toward getting ready for the thalassemia launch, we anticipate that growth will be more muted from here, with quarter-over-quarter variability in PKD revenues. Cost of sales for the quarter totaled $1.5 million. R&D expenses came in at $77.4 million for the second quarter, which is up $8.5 million from the second quarter of 2023. That year-over-year increase was mainly driven by higher costs tied to the TMPRSS6 program that we in-licensed from Alnylam last year. SG&A expenses reached $35.5 million in the second quarter, an increase of $5.1 million over the same quarter in 2023. The main driver there was a rise in commercial-related activities as we get ready for a possible approval of PYRUKYND in thalassemia. As a reminder, during this quarter we announced that the company has agreed to sell the rights to its 15% royalty on potential U.S. net sales of Servier's vorasidenib to Royalty Pharma. Per the terms of that agreement, Agios will get an upfront payment of $905 million once the FDA approves vorasidenib, and Royalty Pharma will get the full 15% royalty on annual U.S. net sales of vorasidenib up to $1 billion, plus a 12% royalty on annual U.S. net sales above $1 billion. Agios will keep a 3% royalty on annual U.S. net sales above $1 billion. On top of that, we still hold the right to a potential $200 million milestone from Servier upon FDA approval of vorasidenib, coming from the divestiture of our oncology business. So in total, Agios will receive $1.1 billion in payments if the FDA approves vorasidenib. As a reminder, the PDUFA action date has been set for August 20, 2024; we closed the quarter with cash, cash equivalents, and marketable securities of $645.3 million. We believe this balance, along with anticipated product revenues, interest income, and payments upon FDA approval of vorasidenib, will give us the financial independence to prepare for potential PYRUKYND launches in thalassemia and sickle cell disease, and to expand our pipeline opportunistically through assets discovered both internally and externally. We continue to focus on creating shareholder value, including by proactively managing our cost base and taking a disciplined approach to cash allocation as we get ready to support potential future launches of PYRUKYND. With more possible milestones ahead that could create value soon, I have confidence that our solid balance sheet will keep letting us act from a position of strength. Now I'll hand the call back to Brian so he can give his closing remarks.
Brian Goff
executiveAppreciate that, Cecilia. Because of an innovative and distinct mechanism of action that enhances red blood cell health, mitapivat has kept producing favorable late-stage results across 3 hemolytic anemias, and it's a pleasure that we have now wrapped up our initial Phase III study in a pediatric patient group. Given this steady and persuasive body of data along with the proven caliber of the Agios team, our belief remains that mitapivat is set to turn into a first-in-class as well as best-in-class therapeutic choice across numerous indications and to grow into a multibillion-dollar franchise. We are concentrating entirely on thalassemia, where our goal is to submit an sNDA before this year ends and pursue a label encompassing people who live with every subtype of the illness. As we keep moving forward toward fulfilling our ambition of turning into a top rare disease company, we will keep working to act as prudent caretakers of our balance sheet and to assess significant chances for creating value. Last, I want to express gratitude to each of our staff members for the effort and commitment they show toward our mission of creating and providing transformative medicines that lift up and prolong the lives of patients dealing with rare diseases, and to all of our partners, among them the patients, physicians, caregivers and participants in our clinical development programs. Having said that, we will now start the Q&A portion of the call.
Eric Schmidt
analystCongratulations on the ongoing achievements. Perhaps I'll inquire regarding today's fresh update, the NewBridge deal. Could you share a bit additional detail on a few of the financial aspects there and what you anticipate gaining? And possibly also discuss the schedule now that you've got Breakthrough Designation in Saudi Arabia.
Brian Goff
executiveThank you, Eric. And Tsveta put in a lot of effort alongside a fairly big group on this recent agreement involving NewBridge and GCC. You're aware that this represents our second biggest market for thalassemia and the top one beyond the U.S. So I'll hand it over to Tsveta to speak on that.
Tsveta Milanova
executiveNo, that's fantastic. And we're genuinely, genuinely thrilled to share news of the deal with NewBridge, since we put a lot of effort into finding a partner possessing deep, solid expertise in the area to serve as our representative for Agios. And we're also extremely proud to share that we did in fact get the Breakthrough Medicine Designation from the Saudi FDA, and Saudi Arabia happens to be the largest market in that region. And we're eager to collaborate with NewBridge in order to leverage the Breakthrough Designation and file for regulatory approval for thalassemia at the earliest opportunity, and we'll share additional details on that once we move into the process. If you consider the numeration agreement we signed with them, they operate as full-service distributors, meaning they handle our products end to end, from regulatory approval through commercialization efforts throughout the entire region — it's a quite standard arrangement for this kind of relationship, essentially a revenue split yield. So there won't be any upfront payment coming to us at Agios. And as we keep moving forward with commercialization, a revenue split will be included as part of that. Looking at the region, we're genuinely, genuinely enthusiastic about what our product can do, because beyond the fact that there's a significant unmet medical need there, we've also run clinical studies in that region. So a person experience already exists with several of the leading centers and KOLs in that area, and we're eager to bring access to patients.
Sarah Gheuens
executiveAnd then Eric, regarding your follow-up about when we'll interact with regulators — naturally, we're really eager to continue advancing our program's development; in fact, we'll begin collaborating with regulators everywhere as quickly as possible.
Brian Goff
executiveTo wrap up, I want to mention that receiving that breakthrough medicines designation in Saudi Arabia is quite rare. We're happy to have it, since—as Tsveta pointed out—it acknowledges a truly significant unmet need in that area. That makes it a key piece for us as we prepare to grow our footprint beyond the U.S. and zero in especially on those regions with serious unmet needs.
Chris Raymond
analystA couple of quick things from my side. With vorasidenib's PDUFA date approaching, as mentioned in your press release, you stand to receive a fairly significant influx of cash. Brian, you've discussed M&A before, and I'd characterize your prior comments as somewhat conservative. However, an injection exceeding $1 billion would presumably alter the scale and reach of what's possible. Could you share how you're thinking about M&A as a tool following the August 20 PDUFA? Then I have one more question.
Brian Goff
executiveYes, absolutely; thank you very much. First, let me say once more how proud I am of Cecilia's efforts on the vorasidenib royalty monetization. That represents a significant milestone. As an aside, vorasidenib is itself a testament to Agios science at its finest. It matters greatly for patients. Naturally, it contributes to strengthening our balance sheet potential; so when you bring up M&A, perhaps I'll elevate the discussion and address capital allocation overall. Our guiding principle is using capital efficiently, period. This definitely places us in a strong position. Above everything else, our highest priority is getting ready for and executing on the crucial launches coming soon. We're genuinely enthusiastic that, if successful, these could be consecutive launches. Thalassemia — Tsveta and the team are getting ready for next year. And as we said in our remarks, regarding sickle cell disease, the RISE UP trial remains on schedule to finish enrollment by year end; that leads to a data readout next year and, once more, the prospect of consecutive launches. So that's priority #1. Second, we keep making excellent strides in moving our internal pipeline forward. Naturally, some capital will go toward that. A prime illustration is MDS. We look forward to starting the Phase IIb study for low-risk MDS. That market is expanding impressively, and we're quite excited about its potential. That's, incidentally, with tebapivat, which we were happy to unveil today as our INN for the compound previously called AG-946. Then, regarding your point, Chris, on business development more generally, it's always something we focus on. That being said, we remain highly disciplined since we have plenty of internal organic opportunities too. Cecilia and the team excel at ensuring our evaluation of what generates the most value-enhancing opportunity undergoes a rigorous and highly competitive process. BD, all of that is definitely on our radar. But once again, strong organic opportunities exist as well.
Chris Raymond
analystAll right, that's helpful. And perhaps one brief additional question. Regarding sickle cell and what it could mean for us, a few key opinion leaders have told us that VOCs don't occur in every single person with sickle cell disease. Could you share your perspective on VOCs as an endpoint, and how broadly it might apply across the patient population?
Brian Goff
executiveAbsolutely — that one is perfect for Sarah.
Sarah Gheuens
executiveAppreciate that. You've got a point there — not every patient had VOCs. And as you're aware, what we're aiming for is a product capable of addressing every facet of sickle cell disease. That means hemolytic anemia along with sickle cell pain crises. As a matter of principle throughout our various programs, we hold the belief — grounded in how our drug's mechanism of action works — that it can be effective across the entire disease spectrum, meaning a range of hemoglobin levels and a range of sickle cell pain crises. From a clinical trial standpoint, though, if your goal is to capture a treatment effect, you have to enroll a patient population where enough of the event is occurring to actually measure that reduction. That's the reason our clinical trial, from an endpoint standpoint, carries an inclusion criterion of 2 or more sickle cell pain crises. But I mean, simply to be in a position to measure that treatment, what we anticipate is that it can work regardless of how many sickle cell pain crises you have — even just 1 or 0. Sadly, that patient population cannot get into the trial, since measuring a treatment effect in them across the year wouldn't be possible. Once again, the drug is intended to tackle all aspects of sickle cell disease, and our intent would consequently be — drawing on the data we've generated throughout the program, including every one of our clinical trials — to pursue a label that can treat sickle cell disease following regulatory review.
Brian Goff
executiveOn that note, Sarah, perhaps you’d also like to weigh in on fatigue, since we make a real effort not to treat these conditions as overly simple—sickle cell disease in particular is extremely complicated. Within sickle cell pain crises, VOCs represent one element, yet fatigue is a separate and deeply serious need.
Sarah Gheuens
executiveOkay, so I just referred to the main endpoint — that hemoglobin primary endpoint, along with the other primary goal of lowering sickle cell pain crises, so we can gauge the impact on hemolytic anemia and VOC. As you're aware, that's backed up by a number of additional secondary endpoints, and one of them specifically targets fatigue, since that's what we keep hearing from patients and physicians — that fatigue carries an extremely heavy and very burdensome impact for this patient population. That's consistent across all of our trial designs. We genuinely aim to bring patient input into the process, which is why we made fatigue the key secondary endpoint. As you know, we recently shared the thalassemia trial results, ENERGIZE, where for the first time we hit our key secondary endpoint on the patient-reported Alco measuring fatigue; so we have strong hopes for the rise of the study as well.
Gregory Renza
analystMorning, Brian and everyone. As usual, congratulations on the steady advancement. Brian, perhaps I'll kick things off with ACTIVATE-KidsT, and maybe direct this to Sarah. Sarah, could you walk us through the statistical assumptions? To us, it definitely looks like the treatment effect carries clinical significance. The findings are mostly in line with what was seen in the adult studies. Did the trial lack sufficient power? Was there a placebo response that might have been consistent, and also consistent with historical rates of transfusion? Any extra detail you can provide would be wonderful. Then I have one more question after that.
Sarah Gheuens
executiveCertainly. I appreciate the question. For ACTIVATE-KidsT, our aim was truly to create a trial suited to a population with an ultra-rare disease, so we opted to heavily utilize the adult data already in hand, in order to reach a sample size fitting for this stage of development that would yield sufficient data for us. Consequently, we must rely on a rather intricate statistical approach when evaluating the primary endpoint of transfusion reduction. As I noted, it's quite intricate since it hinges on how much information you draw from the adult trial. That produces particular weights which you apply when examining your pediatric data. And we cannot claim that a treatment effect appears universally; that's the reason we were so precise in the press release regarding our low or moderate borrowing of the adult study data, because although the data show positive loss ratios, the confidence intervals surrounding those include 1. That's why we remain very cautious about it. To your point, the data we've seen, the reality that 6 patients turned transfusion-free — keep in mind, this is a population that gets transfusions regularly, meaning they receive many transfusions upon entering the trial, and now these patients are transfusion-free. That's a definitive sign of a treatment effect within that particular patient population. And if you happen to be 1 of those 6 children, that represents an extremely significant change for that individual and their family, since this clearly affects the family too. That's why we're genuinely thrilled with the results, because we truly believe there's a meaningful story emerging from this trial. The primary objective, of course, for this trial — something we're also very pleased about — is the safety evaluation, correct? This marks our initial pediatric clinical trial following the completion of an adult program and securing an indication statement there. So this is our first attempt to genuinely broaden the age range for that patient population. From that angle, we believe the safety data matters greatly, the efficacy data we've produced is highly encouraging, and we're eager about what comes next in development.
Gregory Renza
analystThat's useful. And I have one more item. Regarding thalassemia, it's good that Tsveta can go through part of the messaging plus some of the characteristics that physicians might appreciate. I'm curious whether you have any views on potential real-world usage patterns if everything proceeds as expected and approval is granted. As for patients potentially remaining on the therapy for a longer duration, any expectations or perspectives on patients who perhaps experience less hemoglobin improvement benefit, yet possibly more meaningful quality of life gains, or who stay on the therapy? And do you have any views on what amount of hemoglobin improvement we would expect for those patients to remain on the therapy longer term?
Brian Goff
executiveThat's quite a bit there, Greg. So perhaps we'll just concentrate on the heart of your question, which I understood was centered on the unmet need; and I believe Tsveta could definitely add some color to that since we just came back from — she mentioned in her prepared remarks, The Cooley's Anemia Foundation Meeting, which is the yearly gathering for thalassemia patients in the U.S. It's a rather inspiring venue to be at and certainly drives home the extent of unmet need that exists, bearing in mind these are the engaged patients. These are the ones that are in fact skewed toward transfusion dependency and go to meetings like that. But Tsveta possesses many insights that we're continuing to build upon.
Tsveta Milanova
executiveAbsolutely. I'll kick things off, and then perhaps I can pass it to Sarah so she can discuss a bit how broadly our mechanism of action may apply across hemolytic anemia, specifically thalassemia. Absolutely — Brian and I made it to the Cooley's Anemia Foundation Patient and Family Conference, and honestly, it was deeply, deeply touching. We got the chance to sit down with a large number of patients as well as their treating doctors, to listen and pick up insights about what the patient journey looks like and the stories people told there. Just as importantly, we could sense how thrilled and energized both the patients and the clinicians were about the possibility of new innovative treatments making their way into the thalassemia field — among them potentially Mitapivat, should it win approval for that indication in the U.S. Of course, you won't find a more involved or better-informed group than this one, so receiving their input was a fantastic experience. As you mentioned, Greg, feedback from doctors and market studies made it obvious that when choosing a therapy, they consider every meaningful endpoint from our trials as part of the patient profile — hemoglobin, how many transfusions are needed, iron buildup, and of course, fatigue. Sarah also covered just how much fatigue matters for people with thalassemia and sickle cell disease. For the commercial rollout, our goal is to connect with a far wider group — physicians as well as patients. We're putting real effort into disease education, making the case for why raising hemoglobin and addressing hemolysis matters so much, since hemolysis has a genuine connection to the emergence of disease complications and may drive higher rates of illness and death among those patients. You touched on which patient group we expect to target first once we launch, and how we'd broaden that down the road. Thinking about what doctors told us regarding patient traits, every one of them seems ready to write a prescription. If you think about the people who tend to engage most consistently with the healthcare system, those are the ones receiving transfusions, since they're seeing their clinicians on a routine basis while getting those transfusions, plus the ones dealing with more symptoms — whether that's other conditions tied to the disease, or reduced hemoglobin and exhaustion. Our expectation is that these individuals will likely learn about and be evaluated for Mitapivat dives early on in the launch. Then, as we work on educating the clinical and patient communities about the product, we intend to reach a wider group of patients. At this point, I'll pass things along to Sarah, who will discuss why Mitapivat's mechanism of action matters and how we address thalassemia as a whole.
Sarah Gheuens
executiveAppreciate it, Tsveta. Let me return to the hemoglobin thresholds used in the trials. As you're aware, the endpoint we examine in the trial is a rise of 1 gram per deciliter or greater. That said, Greg, as you noted, certain patients might fall short of that responder threshold in the trial yet still gain something from treatment, and we've observed this within our PKD patient group. The same pattern shows up among those with thalassemia. At < >, Dr. Taher presented a waterfall plot illustrating the hemoglobin distribution for patients given Mitapivat compared with those given placebo. In the thalassemia population, you'd notice a chart quite like the one we previously presented for the pyruvate kinase deficiency population. So clearly some individuals are gaining improvements in their hemoglobin levels without hitting the trial's endpoint, which is among the reasons why establishing points such as the hemolysis component matters, and why how patients feel matters. That's why we let patients and physicians choose, once a trial concludes, to move into an open-label extension regardless of whether they met the trial's requirements.
Divya Rao
analystCongratulations on the quarter. Divya here, filling in for Mark. My question concerns ACTIVATE-KidsT. When it comes to the adverse events seen in that study, might you say whether sex hormone levels differ at all between the Mitapivat group and the placebo group? Then I have one more thing to ask.
Sarah Gheuens
executiveAppreciate that question. Beyond the details we released in the press release, we haven't yet provided more extensive safety information, so we're eager to share that at a future medical meeting.
Divya Rao
analystThen, regarding AG-946, I was wondering when — at what point might we anticipate seeing the Phase IIa results? And would that come at a medical meeting, or is that...
Brian Goff
executiveTo start, Divya, we need to get used to saying tebapivat since < > and we'll attempt to do likewise, as 946 is stuck in our minds, though Sarah < >
Sarah Gheuens
executiveTo be honest, those figures remain seared into my memory too. So I apologize in advance if I mix them up. But yeah, as I said, the Phase IIb is where our attention and our current milestone sit right now. The team is extremely, extremely centered on it. So at a later point we'll make a declaration, when we've presented the IIa data at a suitable moment, and that will happen at a medical event coming up.
Brian Goff
executiveLet me stress once more, and this will become clearer as we move forward with the clinical trial program, that MDS represents a highly attractive opportunity for us. We definitely observed the sales figures Reblozyl reported not long ago, which now indicate an annualized run rate above $1.6 billion. Within this patient population, unmet need remains extremely high. As with every disease we go after, there is space for more than one mechanism of action. Should we succeed, this would be not just a first-of-its-kind PK activator, but one delivered as a pill, something that would matter enormously to patients.
Salveen Richter
analystThis is Lydia calling in for Salveen. I have one more question regarding thalassemia. The complete Phase III ENERGIZE-T results are going to be presented at a medical conference later in 2025 — could you set expectations for what we might see, in terms of further insights or data points that could be applied when thinking about clinical meaningfulness?
Sarah Gheuens
executiveYes, so in the press release we emphasized — since it concerns the primary endpoint and one of the secondary endpoints was transfusion independence — we will of course draw attention to that once more, as we are extremely pleased with it. As I mentioned, all key secondary endpoints were also achieved, and we'll be presenting the < > data too, plus safety, naturally. So this will be a standard intent-to-treat analysis presentation, consistent with how we designed and conducted the trial and performed the prespecified analysis; we're very pleased with the results. Among the key secondary endpoints, you might notice that the interval over which we measure a transfusion reduction for the first time is actually quite long. And so, once again, we're of course very happy with what that trial produced. Both studies have now finished and their data have been read out. So we're very eager to advance into development and regulatory engagement, and we look forward to the review getting underway.
Tessa Romero
analystRegarding U.S. regulation, specifically for thalassemia, what should we view as the key gating items right now for your sNDA filing? Also, does the base case involve a standard review or a priority one? Our next question is just a follow-up about the NewBridge deal. What's the earliest point at which we might begin seeing revenue from it? And within the Saudi region, how many patients have thalassemia specifically?
Brian Goff
executiveSarah, would you like to begin on the regulatory pathway?
Sarah Gheuens
executiveAbsolutely. We're really looking forward to collaborating with the FDA and getting the package in for their review and assessment. So it's a standard process, honestly. We don't say anything about timing or method — those are milestones down the road. So I'd say we're just happy with how far our team has come, and we're very excited to get it all underway.
Brian Goff
executiveAnd then new Cecilia, sorry Tsveta, NewBridge GCC?
Tsveta Milanova
executiveRegarding GCC, as previously noted, we are extremely thrilled to have entered into an agreement with NewBridge to handle the subsequent phases of getting ready for submission and possible commercialization, since the GCC ranks as our second most significant region behind the U.S. On the subject of timelines for submission and approval, we will begin collaborating with NewBridge. Specific timelines for that have not been given; it is — roughly 70,000 thalassemia patients exist in the region as we commence working alongside NewBridge to enhance our comprehension of the market. Perhaps we can share additional details, though not at this point.
Brian Goff
executiveIt's obvious that the biggest piece of this is Saudi Arabia. That much is quite evident. Would you mind offering just a brief remark about the access pathways in that region?
Tsveta Milanova
executiveCertainly. If we consider the GCC area, the most useful frame is probably more like how Europe handles pricing and reimbursement assessment. You submit, then reach a pricing and reimbursement agreement, then uptake occurs. It all begins with filing at the regulatory stage, where a price is secured nationally. After that, depending on which market, many additional stages exist before formulary approval and alignment with health institutions and other local hospitals in the private sector. As time passes, we anticipate tenders appearing across the various markets, and we are eager to collaborate with NewBridge to steer through each of these critical milestones toward patient access and accelerate the timeline as much as possible.
Brian Goff
executiveTess, that deal has us genuinely enthusiastic. Still, to circle back: without question, the U.S. sits at the very top of our list. And once more, we feel great about this chance; Tsveta has been collaborating quite forcefully alongside the commercial group to strengthen our commercial capabilities in rare diseases, carrying forward the traction we've gained in PKD while expanding into thalassemia and, we hope, past sickle cell too.
Alec Stranahan
analystWe've got a couple of things. To start, a follow-up regarding that sNDA filing and how we should think about the information going into it. Should we expect the entire dataset by the close of this year — essentially the whole picture the FDA is going to review? And is there anything additional on efficacy coming from that update, or is it mostly about broadening the safety and secondary data? Then a second item about the PK trial in the non-transfusion population scheduled for next year. Can anything be inferred from today's data that applies to that trial, given that the primary endpoints and the patient group are clearly not the same?
Brian Goff
executiveOf course. Appreciate it, Alec. We'll handle them one at a time; and Sarah, perhaps you could begin by addressing the data package we have planned. After that, we'll move on to pediatrics.
Sarah Gheuens
executiveAs I mentioned, the program has now reached the point where both of the 2 randomized clinical trials are finished and the databases are locked, so the data is in hand. We're quite enthusiastic about pulling all of that together. We're essentially carrying out the usual kind of work that would be expected ahead of submissions, following the standard cut timelines along with the updates that have to be made, and we're very keen to engage with the regulators and get that effort underway. There are invariably exchanges of questions in both directions. So, I mean, we'll simply proceed through each step. Turning to the endpoints for ACTIVATE-KidsT, we're extremely happy with what the data from this clinical trial showed, on both the safety side and the efficacy side.
Brian Goff
executiveRight. And then what are your thoughts on the link, or the read-through as you'd call it, to the non-transfusion-dependent patients in ACTIVATE-Kids?
Sarah Gheuens
executiveTo reiterate, ACTIVATE-Kids follows a comparable approach. This involved a blinded group of patients who don't receive transfusions on a regular basis. We're really looking forward to reaching the upcoming milestone, after which we'll receive that set of data. In the ACTIVATE-KidsT study, we're quite encouraged, since the response of being free from transfusions really underscores how Mitapivat's mode of action can apply to pediatric patients too. And now our hope is that this carries over into the other study as well.
Brian Goff
executiveThank you, Justin, and much appreciated to all of you for the excellent questions and for joining us on today's call; obviously this is a really thrilling moment for Agios. And when I look back at the year up to now, things have felt a bit nonstop, in the very best sense, as we keep hitting our milestones, and perhaps even more significantly, there's plenty still ahead that we're eagerly anticipating; so we hold a firm belief that we are positioned to bring breakthrough new treatments to patients and, in the end, to generate substantial value for shareholders over the long term as well. So once more, thank you, and we can't wait to talk with you again before long.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.